Description
PRIMARY OBJECTIVE:
I. To evaluate pain response by 14 gray (Gy) single fraction (SF)-BgRT for patients with painful bone metastases.
SECONDARY OBJECTIVE:
I. To evaluate patient-reported health related quality of life (QOL), clinician-rated toxicity per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0, radiographic evidence of disease progression at treated sites, and rate of re-irradiation.
OUTLINE:
Patients undergo a single fraction of BgRT on day 0. Patients undergo positron emission tomography (PET)/computed tomography (CT) on study and optionally during follow up.
After completion of study treatment, patients are followed up at 2 weeks, 3 months and then every 3 months for up to 1 year.